国际检验医学杂志
國際檢驗醫學雜誌
국제검험의학잡지
INTERNATIONAL JOURNAL OF LABORATORY MEDICINE
2009年
10期
960-962
,共3页
格雷夫斯病%抗甲状腺过氧化物酶抗体%131I治疗%甲状腺机能减退
格雷伕斯病%抗甲狀腺過氧化物酶抗體%131I治療%甲狀腺機能減退
격뢰부사병%항갑상선과양화물매항체%131I치료%갑상선궤능감퇴
Graves' disease%And-thyroid peroxidase antibody(TPOAb)%131I treatment%Hypothyroidism
目的 探讨Graves甲状腺功能亢进症(简称甲亢)131I治疗前后动态监测抗甲状腺过氧化物酶抗体(TPOAb)水平变化及其对治疗效果及预后的评判价值.方法 112例Graves甲亢患者和50例健康对照者分别于131I治疗前及治疗后3、6、12和24个月采用化学发光法(CLIA)测定其血清TPOAb水平.数据用x-±s表示,组间差异用方差分析与t检验.结果 112例Graves甲亢患者在131I治疗前血清TPOAb水平[(81.95±47.64)IU/mL]高于健康对照组(P＜0.01).在131I治疗后3个月血清TPOAb水平[(108.94±70.15)IU/mL]明显高于治疗前(P＜0.01),治疗后6个月患者血清TPOAb水平[(42.78±28.68)IU/mL]开始降低,但与对照组比较差异仍有统计学意义(P＜0.01),在131I治疗12个月后血清TPOAb水平[(19.56±10.39)IU/mL]明显降低(P＜0.01),到24个月患者血清TPOAb水平[(7.89±4.01)IU/mL]与对照组比较差异无统计学意义(P＞0.05).结论 在131I治疗前检测血清TPOAb水平可作为131I用量的辅助指标;在131I治疗后检测Graves甲亢患者的TPOAb水平有助于随访监测及疗效评价,还可了解治疗后的免疫反应状态.
目的 探討Graves甲狀腺功能亢進癥(簡稱甲亢)131I治療前後動態鑑測抗甲狀腺過氧化物酶抗體(TPOAb)水平變化及其對治療效果及預後的評判價值.方法 112例Graves甲亢患者和50例健康對照者分彆于131I治療前及治療後3、6、12和24箇月採用化學髮光法(CLIA)測定其血清TPOAb水平.數據用x-±s錶示,組間差異用方差分析與t檢驗.結果 112例Graves甲亢患者在131I治療前血清TPOAb水平[(81.95±47.64)IU/mL]高于健康對照組(P＜0.01).在131I治療後3箇月血清TPOAb水平[(108.94±70.15)IU/mL]明顯高于治療前(P＜0.01),治療後6箇月患者血清TPOAb水平[(42.78±28.68)IU/mL]開始降低,但與對照組比較差異仍有統計學意義(P＜0.01),在131I治療12箇月後血清TPOAb水平[(19.56±10.39)IU/mL]明顯降低(P＜0.01),到24箇月患者血清TPOAb水平[(7.89±4.01)IU/mL]與對照組比較差異無統計學意義(P＞0.05).結論 在131I治療前檢測血清TPOAb水平可作為131I用量的輔助指標;在131I治療後檢測Graves甲亢患者的TPOAb水平有助于隨訪鑑測及療效評價,還可瞭解治療後的免疫反應狀態.
목적 탐토Graves갑상선공능항진증(간칭갑항)131I치료전후동태감측항갑상선과양화물매항체(TPOAb)수평변화급기대치료효과급예후적평판개치.방법 112례Graves갑항환자화50례건강대조자분별우131I치료전급치료후3、6、12화24개월채용화학발광법(CLIA)측정기혈청TPOAb수평.수거용x-±s표시,조간차이용방차분석여t검험.결과 112례Graves갑항환자재131I치료전혈청TPOAb수평[(81.95±47.64)IU/mL]고우건강대조조(P＜0.01).재131I치료후3개월혈청TPOAb수평[(108.94±70.15)IU/mL]명현고우치료전(P＜0.01),치료후6개월환자혈청TPOAb수평[(42.78±28.68)IU/mL]개시강저,단여대조조비교차이잉유통계학의의(P＜0.01),재131I치료12개월후혈청TPOAb수평[(19.56±10.39)IU/mL]명현강저(P＜0.01),도24개월환자혈청TPOAb수평[(7.89±4.01)IU/mL]여대조조비교차이무통계학의의(P＞0.05).결론 재131I치료전검측혈청TPOAb수평가작위131I용량적보조지표;재131I치료후검측Graves갑항환자적TPOAb수평유조우수방감측급료효평개,환가료해치료후적면역반응상태.
Objective The investigate the clinical significance of serum anti-thyroid peroxidase antibody(TPOAb)monitoring in therapeutic effect judgment and prognosis evaluation during 131I treatment in patients with Graves disease.Methods A total of 112 patients with Graves disease(hyperthyroidism group)and 50 healthy controls(healthy control group)were enrolled in the investigation.Serum concentration of TPOAb was measured with chemiluminescent immunoassay(CLIA)in healthy control group and hyperthyroidism group(at time points of 0,3,6,12 and 24 months after 131I treatment,i.e.T0,T3,T6,T12 and T24).Variance analysis and t test were adopted.Results The mean level of TPOAb was significantly higher in patients with Graves' disease before 131I treatment than that in healthy controls(P＜0.01).In hypenthyroidism group,serum concentration of TPOAb was evidently higher at T3[(108.94±70.15)IU/mL]than T0[(81.95±47.64)IU/mL](P＜0.01);TPOAb level began to decline at T6[(42.78±28.68)IU/mL],but still higher than that of healthy control group;while where was no statistical difference in TPOAb level between hyperthyroidism group at T24[(7.89±4.01)IU/mL]and healthy control group(F＞0.05).Conclusion Serum level of TPOAb before treatment may be used as an auxiliary indicator of 131I dosage.Posttreatment TPOAb level monitoring contributes to therapeutic effect evaluation,follow-up visit and immunorcaction state understanding.
